tiprankstipranks
Trending News
More News >
Galectin Therapeutics Inc (GALT)
NASDAQ:GALT
US Market

Galectin Therapeutics (GALT) Income Statement

Compare
660 Followers

Galectin Therapeutics Income Statement

Last quarter (Q3 2025), Galectin Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q3, Galectin Therapeutics's net income was $-8.18M. See Galectin Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -37.00K$ -33.00K$ -32.00K$ -41.00K$ -36.00K
Operating Expenses
$ 42.40M$ 38.04M$ 38.32M$ 30.14M$ 23.41M
Depreciation and Amortization
$ 37.00K$ 33.00K$ 32.00K$ 41.00K$ 36.00K
EBITDA
$ -41.47M$ -38.24M$ -37.71M$ -30.00M$ -23.34M
Operating Income
$ -42.43M$ -38.07M$ -38.35M$ -30.18M$ -23.44M
Other Income/Expenses
$ -4.61M$ -2.99M$ -424.00K$ -348.00K$ -21.00K
Pretax Income
$ -47.05M$ -41.07M$ -38.78M$ -30.53M$ -23.46M
Net Income
$ -47.05M$ -41.07M$ -38.78M$ -30.53M$ -23.46M
Per Share Metrics
Basic EPS
$ -0.76$ -0.74$ -0.65$ -0.52$ -0.41
Diluted EPS
$ -0.76$ -0.74$ -0.65$ -0.52$ -0.41
Weighted Average Shares Outstanding
62.31M 60.16M 59.39M 58.53M 57.03M
Weighted Average Shares Outstanding (Diluted)
62.31M 60.16M 59.39M 58.53M 57.03M
Currency in USD

Galectin Therapeutics Earnings and Revenue History